Your mandated EU point of contact under Article 22 of the AI Act
Guides to Regulation (EU) 2024/1689, as amended by Regulation (EU) 2026/1744, for AI providers established outside the EU.
Checklist of what providers of high-risk AI systems must do under Article 16 AI Act: Chapter III requirements, quality management system, technical documentation, logs, conformity assessment, registration and post-market duties.
How high-risk AI systems are assessed under Article 43 AI Act - internal control (Annex VI) or notified body (Annex VII) - followed by the EU declaration of conformity, CE marking and registration in the EU database.
What providers of general-purpose AI (GPAI) models must do under Articles 53-55 AI Act: documentation, copyright policy, training-data summary, systemic-risk duties, and the Article 54 authorised representative for non-EU providers.
Article 50 AI Act transparency obligations for chatbots, machine-readable marking of AI-generated content, emotion recognition and deepfake disclosure - with the 2 August 2026 and 2 December 2026 dates.
The AI practices banned by Article 5 AI Act since 2 February 2025 - manipulation, social scoring, untargeted facial scraping, workplace emotion recognition and more - plus the non-consensual intimate imagery and CSAM bans added by Regulation (EU) 2026/1744.
What companies that use high-risk AI systems must do under Article 26 AI Act - instructions, human oversight, logs, informing workers and affected people - and who must carry out a fundamental rights impact assessment under Article 27.
When AI-enabled medical devices are high-risk under the AI Act, the 2 August 2028 date, a single conformity assessment through the MDR/IVDR notified body, and the separate MDR and AI Act authorised representative roles.
The AI Act fine levels under Articles 99 and 101: up to EUR 35 million or 7% for prohibited practices, EUR 15 million or 3% for other obligations including those of authorised representatives, and the SME rules.
What the authorised representative role does and does not do.
Start here if you are unsure whether Article 22 applies.
Annex III categories and screening questions.
Key dates after Regulation (EU) 2026/1744.
Triage for providers and SaaS companies.